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APIC Conference Is Here 
Are you going to the Association for Professionals in Infection Con-
trol and Epidemiology, Inc., (APIC) 2010 National Conference in 
New Orleans in July? If you are, we’d love to see you at one (or more) of the NHSN educational 
sessions. Take a look at the list below to see if there is one that may be right be for you. 
Monday, July 12th 
Conference Auditorium 2:  
3:00-5:00 PM 
Getting It Right! Learning How to Use the NHSN Surveillance Definitions 
Teresa Horan, MPH, Leader, NHSN Training and User Support Team 
Conference Auditorium 1: 
5:15-6:15 PM 
NHSN Member’s Meeting 
NHSN Team Members 
Wednesday, July 14th
       Conference Auditorium 1: 
1:30 PM - 2:30 PM 
Overview of Antibiotic-Resistant Infections Reported to NHSN: Problematic Pathogens and 
Best Metrics
Dawn M. Sievert, PhD, MS , Epidemiologist
2:45 PM-3:45 PM 

NHSN Healthcare Personnel Safety Component 

Taranisia MacCannell, PhD, Healthcare Epidemiologist
 
4:00 PM - 5:00 PM 
Making the Most of Your NHSN Data
Maggie Dudeck, MPH, CPH , Epidemiologist
Influenza Vaccination Module - Update for 2010!... Continued on pg 2
The High Risk Inpatient Influenza Vaccination (HRIIV) Module will be updated for the 2010-11 
influenza season to reflect the latest recommendations of the Advisory Committee on Immuniza-
tion Practices (ACIP) and will be renamed the Vaccination Module.  This module assists facilities to 
document the offering and administration of influenza vaccine in the hospitalized inpatient popula-
tion. The module has capability for the facility to identify, analyze and provide a standardized way 
to track the vaccination of hospitalized inpatients. It will be streamlined and simplified for ease of 
use by facilities. 
 In February, 2010, ACIP voted to expand the recommendation for annual influenza vaccination to 

include all people aged 6 months and older for the 2010 – 2011 influenza season. The new recom
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Influenza Vaccination Module... Continued from pg 1
recommendation seeks to remove barriers to influenza immunization and sig-
nals the importance of preventing influenza across the entire population. This 
change occurred as a response to incremental increases in the numbers and 
groups of people recommended for influenza vaccination in previous years,
and lessons learned from the H1N1 flu pandemic.  ACIP’s previous recommen-
dations for seasonal influenza vaccination focused on vaccination of higher risk 
persons; therefore, the HRIIV Module was restricted to such patients. With 
ACIP’s broader recommendations, NHSN will also expand to include all hospi-
talized patients. 
Based on current projections, more licensed types and brands of seasonal 
influenza vaccines will be available in the 2010-11 influenza season than has 
ever been available before.  The composition of the Northern Hemisphere’s
2010-11 seasonal influenza  vaccine will be trivalent (with three different vac-
cine viruses) and include an A/California/7/2009 (H1N1)-like virus, an A/ 
Perth/16/2009 (H3N2)-like virus, and a B/Brisbane/60/2008-like virus. The 
H1N1 virus recommended for inclusion in the 2010-11 trivalent vaccine is a
Biovigilance Component Updates 
pandemic 2009 H1N1 virus and is the 
same virus used in the 2009 H1N1 
monovalent vaccine.
The Vaccination Module can be com-
pleted using either retrospective medi-
cal record review (Vaccination Monthly 
Summary Method) or by prospective 
evaluation of each inpatient admission 
(Patient-Level Vaccination Method). 
The minimum requirement to partici-
pate in this module is one month dur-
ing the influenza season, but maximal 
benefit is obtained by completing the 
module for each month of the entire 
influenza season.
Entering Candida Glabrata 
A new version of the Biovigilance Component containing the most up-to-date 
information was published on the NHSN website June 9, 2010.  The most 
notable changes include detailed instructions for using the Hemovigilance 
Module, including monthly reporting requirements and clarifications to the
case definitions in Appendix A, and the clinical and laboratory definitions in 
Appendix B. 
Note the following changes in case definition criteria: 
 Hypotension has been clarified for children and small infants. 
 FNHTR reaction can now be reported in the patient with chills or 
rigors and absence of fever. 
 TAGVHD probable and possible criteria were clarified. 
The June 2010 release of the BV Component Protocol may be found here:
www.cdc.gov/nhsn/bio.html.
NHSN Case Studies to Hone Your Surveillance Skills 
It has been brought to the attention 
of the NHSN Help desk that when 
entering the pathogen Candida 
glabrata for any sort of HAI event, 
the system is requiring you to enter 
at least one antimicrobial with sus-
ceptibility results in order to save 
the event. Currently there are no 
antifungals among the list of antim-
icrobials.  We are working to resolve 
this defect. In the meantime, 
please choose any antimicrobial 
agent from the menu and then indi-
cate “Not Tested” for the result. 
This will allow you to save the 
event. We appreciate your patience 
as we work to resolve this issue. 
The American Journal of Infection 
Control (AJIC) and the National 
Healthcare Safety Network (NHSN) 
have teamed up to present a series 
of case studies in AJIC beginning in 
2010. These cases reflect some of 
the complex patient scenarios infec-
tion preventionists have encountered 
in their daily surveillance of health-
care-associated infections. With each 
case, a link to an online quiz is pro-
vided where you can answer the 
questions and receive immediate 
feedback in the form of answers and 
NHSN e-News 
explanations. All individual partici-
pant answers are confidential, al-
though it is the authors’ hope to 
share a summary of the findings at a 
later date. All cases, answers, and 
explanations have been reviewed 
and approved by the NHSN.  
The first case study and four ques-
tions are published in the June 2010 



















   
   










   
   
 
  
NHSN Patient Safety Manual and Document Updates
The NHSN Manual and documents have been modified to reflect recent changes to processes and proce-
dures made in the NHSN application for the 6.2 release.
Manual and Document Updates 
Manual Chapter: 
1 Overview Removed outdated information about the Biovigilance and Healthcare Personnel Safety Components. 
4 CLABSI Added note on page 4-2: “Intraaortic balloon pumps (IABP) are not central lines.”
Added bullet under Reporting Instructions page 4-5: 
“Even if there are clinical signs or symptoms of localized infection at a vascular access site, but no 
other infection can be found, the infection is considered a primary BSI.” 
9 SSI The following updates were made to ICD-9-CM codes and the listed Operatives Categories: 
CARD: Moved 37.25 from CARD to NO (non-operative)
FUSN: Moved 81.62, 82.63, 81.64 from FUSN to OTH 
PACE: Moved 33.25 from PACE to THOR 
THOR:   Added 32.3, 32.4, and 32.5 to THOR 
VHYST:  Added 68.7 to VHYS 
XLAP: Moved 54.62 from XLAP to NO; Added 53.7 to XLAP
12 MDRO/CDAD Identified that Facility-wide Inpatient, Facility-wide Outpatient and Facility-wide Both are optional 
methods for LabID Event surveillance; Removal of option of calculating a CDI Incidence Rate for a fa-
cility- can only be calculated for a location (has been renamed Location CDI Incidence Rate).
14 Tables of Instruc-
tions 
1. Table 2 BSI, Table 4 PNEU, and Table 5 UTI– Note added to Date of Event: “If a device has been
pulled on the first day of the month in a location where there are no other device days in that 
month, and a device-associated infection develops after the device is pulled, attribute the infection 
to the previous month.” 
2. Table 3 CLIP– Further instructions under Occupation of Inserter and Reason for Insertion.  Central 
Line Exchanged Over Guidewire field removed; Insertion of PICC team, as option for inserter; re-
moval of fields Number of lumens and Antiseptic ointment applied to site.
3. Table 6 Completion of Denominators for Intensive Care Unit– Note added: “If the patient has only  
a tunneled or implanted central line, begin recording days on the first day the line was accessed 
and continue throughout entire stay.” 
4. Table 12 MDRO/CDAD– Completion of the Laboratory-identified MDRO or CDAD Event- System will 
now auto-fill field Documented Prior Evidency of Infection or Colonization with this Specific Organ-
ism Type from a Previously Reported LabID Event.
5. Table 13 Completion of Denominator for Procedure– ASA now required for inpatient procedures 
only; Multiple Procedures field was removed.
15 Locations Addition of Mixed Acuity, Pediatric Mixed Acuity and Mixed Age Mixed Acuity Wards and addition of 
LabID Event locations: Facility-Wide Inpatient, Facility-Wide Outpatient  
16 Key Terms Addition of definition of Aseptically Obtained
Document: 
ICD-9-CM Procedure
Code Mapping to 
NHSN Operative Pro-
cedure Categories 
Updated to reflect changes highlighted above.






















    
CDC/DHQP Visits Facilities in Oregon 
CDC’s Division of Healthcare Quality 
Promotion (DHQP), recently trav-
eled to Portland, Oregon, to attend 
the annual Council for State and 
Territorial Epidemiologists (CSTE) 
conference. In addition to attending 
the conference, DHQP staff had the 
unique opportunity to meet with 
Oregon’s three public health agen-
cies concurrently working on the 
prevention and elimination of
healthcare-associated infections 
(HAI): the Oregon Public Health 
Division (OPHD), Office for Oregon 
Health Policy and Research (OHPR), 
and the Oregon Patient Safety Com-
mission (OPSC).   
Additionally, DHQP’s Surveillance 
Branch coordinated with OHPR’s 
HAI Prevention Coordinator, Jeanne 
Negley, and Bob Duehmig of the 
Office of Rural Health to visit three 
hospitals ranging in bed-size from
25 to 483 beds. The overarching 
goals of the visits were to learn 
first-hand about their experiences 
using NHSN, to determine and re-
solve facility-specific challenges, 
and identify successes in surveil-
lance and reporting of HAIs.
In addition, DHQP’s Wendy Vance,
Public Health Analyst and Ronda 
Sinkowitz-Cochran, Prevention Liai-
son were privileged to participate in
the first OPSC prevention collabora-
tive kick-off meeting on Thursday, 
June 11. Oregon’s HAI prevention 
collaborative consists of infection-
prevention representatives from 
nine Oregon facilities and plans to 
implement proven strategies for 
sustainable change in infection pre-
vention practices as one of the 
many goals and initiatives for HAI
reduction in Oregon.  
Additional kick-off attendee’s in-
cluded the following partners: 
 Oregon Association of Hospitals 
and Health Systems (OAHHS)  
 Acumentra Health  
 Association for Professionals in
Infection Control and Epidemiol-
ogy/ Oregon and Southern 
Washington chapter 
 OPSC faculty and planning com-
mittee.
 The kickoff was facilitated by 
OPSC’s Collaborative Manager, 
Melissa Parkerton. The collaborative 
will have five learning sessions over the course of the next 18 months, 
and will focus on prevention activities, change packages, and bundles for 
the reduction of selected HAI including: Surgical Site Infections by 10%
(stretch goal by 25%), Clostridium Difficile by 12% (stretch goal by 
30%), and Central Line-Associated Bloodstream Infections (CLABSI) by 
20% (stretch goal is 0), with dual enrollment in the OAHHS sponsored 
Stop-BSI Comprehensive Unit-Based Safety Program (CUSP). 
The trip was timely as Oregon released their first annual HAI report on 
May 24, 2010, on CLABSI, SSI, and SCIP process measures. The full re-
port can be viewed at: http://www.oregon.gov/OHPPR/. 
Thanks again to our many partners in Oregon for your hospitality, willing-
ness to share, and for a learning-filled six days! 
During recent site visit to Portland, Oregon, DHQP, OHPR, and hospital staff  dis-
cussed challenges and successes of using NHSN.
Training for State HAI Programs 
Through the American Recovery and Reinvestment Act (ARRA) of 2009, $50 million 
dollars was authorized to support states in the prevention and reduction of health-
care associated infections (HAI).  Many states are using their ARRA funds to
strengthen already present HAI surveillance programs or to develop such a program.  
NHSN has been assisting states through educational offerings and plan to offer webi-
nar presentations aimed to educate state HAI program staff on the use of NHSN.  
State health departments will receive advance notification of the trainings.

















   
  
Q: If a patient has a medi-
port placed in the OR for 
chemotherapy and then is 
discharged, but 8 weeks 
later, after 6 weeks of out-
patient chemotherapy, develops  
fever, malaise and has 2/2 blood 
cultures positive for Staphylococcus 
aureus, is this infection a surgical 
site infection (SSI) related to the 
implant? 
A: No. The NHSN definition of an 
implant is “A nonhuman-derived 
material, or tissue that is perma-
nently placed in a patient during an 
operative procedure and is not rou-
tinely manipulated for diagnostic or 
therapeutic purposes.” Therefore, 
once this device has been accessed 
Did You Know…?
NHSN Questions & Answers   
for therapy, it ceases to be an im-
plant. This means that a subse-
quent infection cannot be an SSI 
regardless of the amount of time 
elapsed since surgery. 
Q:  Is an uncomplicated Cesarean 
Section a wound class 1 or 2? 
A: If the operative case is uncom-
plicated and encounters neither 
evidence of infection, nor contami-
nation of the surgical field, then the 
surgery should be identified as a 
wound class 2, Clean-
Contaminated:  Operative wounds 
in which the respiratory, alimentary, 
genital or urinary tracts are entered 
under controlled conditions and 
without unusual contamination.
Specifically, operations involving the 
biliary tract, appendix, vagina and oro-
pharynx are included in this category, 
provided no evidence of infection or 
major break in technique is encoun-
tered.
1In order to improve overall performance of the NHSN application, you should consider upgrading your Inter-
net browser. While using the NHSN application, Internet 
Explorer 7 and 8 users experience 12%-35% better per-
formance than Internet Explorer 6 users. 
2Some users have been submitting questions related to NHSN to NHSN staff mailboxes directly.  Unless
otherwise directed, please send all questions to 
NHSN@cdc.gov. Sending your questions in this manner 
allows your question to be triaged to an available staff
person and will result in a quicker response to you. We 
thank you for your assistance in this.  
The Centers  for  Disease Contro l  
and Prevent ion (CDC)  
MS-A24 







CDC's NHSN Web site:  www.cdc.gov/nhsn
The National Healthcare Safety Network (NHSN) is a voluntary, secure, inter-
net-based surveillance system that integrates patient and healthcare person-
nel safety surveillance systems managed by the Division of Healthcare Qual-
ity Promotion (DHQP) at CDC. 
During 2008, enrollment in NHSN was opened to all types of healthcare facili-
ties in the United States, including acute care hospitals, long term acute care 
hospitals, psychiatric hospitals, rehabilitation hospitals, outpatient dialysis 
centers, ambulatory surgery centers, and long term care facilities. 
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